TY - JOUR
T1 - Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer
AU - Annels, Nicola E.
AU - Mansfield, David
AU - Arif, Mehreen
AU - Ballesteros-Merino, Carmen
AU - Simpson, Guy R.
AU - Denyer, Mick
AU - Sandhu, Sarbjinder S.
AU - Melcher, Alan A.
AU - Harrington, Kevin J.
AU - Davies, Bronwyn
AU - Au, Gough
AU - Grose, Mark
AU - Bagwan, Izhar
AU - Fox, Bernard
AU - Vile, Richard
AU - Mostafid, Hugh
AU - Shafren, Darren
AU - Pandha, Hardev S.
N1 - Funding Information:
K.J. Harrington reports receiving commercial research grants from Astra-Zeneca, Boehringer-Ingelheim, MSD, and Replimune; reports receiving speakers bureau honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck-Serono, MSD, Pfizer, and Replimune; and is a consultant/advisory board member for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Merck-Serono, MSD, Pfizer, and Replimune. B. Davies holds ownership interest (including patents) in Viralytics. M. Grose is an employee of Viralytics. B. Fox is an employee of UbiVac, Argos, Bayer, Bristol-Myers Squibb, CellDex Therapeutics, Definiens, Janssen/Johnson & Johnson, Macrogenics, AstraZeneca, Akoya/PerkinElmer, and PrimeVax; reports receiving commercial research grants from Viralytics/Merck, Bristol-Myers Squibb, Bayer, Definiens, Janssen/Johnson & Johnson, Macro-genics, NanString, OncoSec, Akoya/PerkinElmer, and Shimadzu; and holds ownership interest (including patents) in UbiVac and PrimeVax. D. Shafren reports receiving commercial research grants from, holds ownership interest (including patents) in, and is a consultant/advisory board member for Viralytics. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019
Y1 - 2019
N2 - Purpose: The CANON [CAVATAK in NON-muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods: Fifteen patients enrolled in this "window of opportunity" phase I study, exposing primary bladder cancers to CAVATAK prior to surgery. The first 9 patients received intravesical administration of monotherapy CAVATAK; in the second stage, 6 patients received CAVATAK with a subtherapeutic dose of mitomycin C, known to enhance expression of ICAM-1 on bladder cancer cells. The primary endpoint was to determine patient safety and maximum tolerated dose (MTD). Secondary endpoints were evidence of viral replication, induction of inflammatory cytokines, antitumor activity, and viral-induced changes in resected tissue. Results: Clinical activity of CAVATAK was demonstrated by induction of tumor inflammation and hemorrhage following either single or multiple administrations of CAVATAK in multiple patients, and a complete resolution of tumor in 1 patient. Whether used alone or in combination with mitomycin C, CAVATAK caused marked inflammatory changes within NMIBC tissue biopsies by upregulating IFN-inducible genes, including both immune checkpoint inhibitory genes (PD-L1 and LAG3) and Th1-associated chemokines, as well as the induction of the innate activator RIG-I, compared with bladder cancer tissue from untreated patients. No significant toxicities were reported in any patient, from either virus or combination therapy. Conclusions: The acceptable safety profile of CAVATAK, proof of viral targeting, replication, and tumor cell death together with the virus-mediated increases in "immunological heat" within the tumor microenvironment all indicate that CAVATAK may be potentially considered as a novel therapeutic for NMIBC.
AB - Purpose: The CANON [CAVATAK in NON-muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods: Fifteen patients enrolled in this "window of opportunity" phase I study, exposing primary bladder cancers to CAVATAK prior to surgery. The first 9 patients received intravesical administration of monotherapy CAVATAK; in the second stage, 6 patients received CAVATAK with a subtherapeutic dose of mitomycin C, known to enhance expression of ICAM-1 on bladder cancer cells. The primary endpoint was to determine patient safety and maximum tolerated dose (MTD). Secondary endpoints were evidence of viral replication, induction of inflammatory cytokines, antitumor activity, and viral-induced changes in resected tissue. Results: Clinical activity of CAVATAK was demonstrated by induction of tumor inflammation and hemorrhage following either single or multiple administrations of CAVATAK in multiple patients, and a complete resolution of tumor in 1 patient. Whether used alone or in combination with mitomycin C, CAVATAK caused marked inflammatory changes within NMIBC tissue biopsies by upregulating IFN-inducible genes, including both immune checkpoint inhibitory genes (PD-L1 and LAG3) and Th1-associated chemokines, as well as the induction of the innate activator RIG-I, compared with bladder cancer tissue from untreated patients. No significant toxicities were reported in any patient, from either virus or combination therapy. Conclusions: The acceptable safety profile of CAVATAK, proof of viral targeting, replication, and tumor cell death together with the virus-mediated increases in "immunological heat" within the tumor microenvironment all indicate that CAVATAK may be potentially considered as a novel therapeutic for NMIBC.
UR - http://www.scopus.com/inward/record.url?scp=85072820084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072820084&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-4022
DO - 10.1158/1078-0432.CCR-18-4022
M3 - Article
C2 - 31273010
AN - SCOPUS:85072820084
VL - 25
SP - 5818
EP - 5831
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 19
ER -